2026-01-23 - Analysis Report
**Comprehensive Analysis of AbbVie (ABBV)**

### Company Overview
AbbVie is a global biopharmaceutical company that discovers, develops, and delivers innovative treatments for various diseases and conditions.

### Return Rate Comparison
- Cumulative return of review stock (ABBV): 180.26%
- Cumulative return of comparison stock (S&P 500, VOO): 92.53%
- Divergence: 82.20 (max: 135.40, min: -20.20, relative divergence: 65.80%)

### Analysis of Performance

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019  | 42.0% | 21.6% | 24.0% | 1.1 | 156.5B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

### Recent Stock Price Fluctuations
- 5-day SMA: $215.88
- 20-day SMA: $223.54
- 60-day SMA: $225.19
- Current Close: $218.11
- Recent fluctuation issue: Sharp rebound, no sharp decline was observed.

### RSI, PPO Index Analysis
- Market Risk Indicator (MRI): 0.90 (High Investment Recommended)
- RSI: 39.69
- PPO: -0.40
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: High
- Recent (20 days) relative divergence change: -2.80 (worsening)
- 7-day Rank change: 2 (rank up)
- 7-day Dynamic Expected Return change: 0.60 (improving)

### Expected Return
- Expected Return (%): 40.20%
- Expected excess return compared to S&P 500 if invested long-term: 40.20%

### Recent News & Significant Events
- March 6th Options Now Available For AbbVie (ABBV) - Nasdaq
- ABBV vs. MRK: An Oncology-Immunology Showdown for Investors - The Globe and Mail
- The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie - The Motley Fool
- What to Expect From AbbVie's Next Quarterly Earnings Report - Yahoo Finance
- AbbVie Inc. $ABBV Shares Sold by Simplicity Wealth LLC - MarketBeat
- The Long-Term Investment Value of Eli Lilly, AbbVie, and Intuitive Surgical - NAI500

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.22 / 289.00 / 184.00

### Comprehensive Analysis
Based on the analysis, AbbVie (ABBV) appears to be a promising investment option with a high cumulative return and high expected excess return compared to the S&P 500. The market risk indicator also suggests a high investment recommendation. However, the recent relative divergence change and 7-day rank change suggest a worsening trend, which should be taken into consideration. The recent news and significant events also highlight the company's growth prospects and dividend potential. Overall, AbbVie (ABBV) seems to be a strong buy with a high target price and potential for long-term growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.